About
Mutated exon replacement
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
63
By Phase
PHASE1/PHASE2: 1
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06445322Lead Sponsor
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials
N/ARecruiting
50 participants
Started: Jun 20, 2024 · Completed: Aug 31, 2030
NCT06467344Lead Sponsor
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
PHASE1/PHASE2Recruiting
13 participants
Started: Jun 11, 2024 · Completed: Dec 1, 2030
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...